PT-141 (Bremelanotide)

Melanocortin Receptor Agonist for Sexual Desire and Arousal

PT-141, also known as bremelanotide, is a synthetic melanocortin receptor agonist developed to support sexual desire and arousal through central nervous system pathways. Unlike traditional sexual-function therapies such as Viagra and Cialis (PDE5 inhibitors) that focus on increasing blood flow to the genitals, PT-141 works directly at the level of the brain, addressing the neurochemical drivers of sexual motivation by activating melanocortin receptors in the hypothalamus.

The FDA approved bremelanotide in 2019 under the brand name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first medication approved specifically for low libido that works through the central nervous system. While only FDA- approved for women, PT-141 is widely used off-label by men for erectile dysfunction and low libido.

PT-141 was developed from Melanotan II, a peptide originally created for skin tanning. During clinical trials, researchers observed that subjects experienced increased sexual arousal as a prominent side effect, leading to the development of PT-141 specifically to isolate and target the sexual effects without the tanning activity.

The peptide is administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity. It is used on an as-needed basis rather than daily, with a maximum of 8 doses per month recommended. For individuals who have not responded to traditional ED medications or who experience desire-related dysfunction rather than purely mechanical issues, PT-141 offers a fundamentally different approach.

How It Works

Mechanism of Action

PT-141 activates melanocortin receptors—primarily MC3R and MC4R—located in the hypothalamus and other limbic regions of the brain. These receptors play a key role in regulating sexual desire, arousal, and motivational behavior. Activation of these pathways increases dopaminergic signaling while reducing inhibitory serotonergic tone. The result is enhanced sexual interest and responsiveness without relying on peripheral vasodilation or direct genital stimulation.

This mechanism distinguishes PT-141 from PDE5 inhibitors and explains why it may be effective even when blood-flow–based therapies are insufficient.

What Happens When PT-141 Binds to Melanocortin Receptors

• It stimulates pathways that increase sexual desire and arousal
• It promotes the release of dopamine, a neurotransmitter associated with pleasure and

motivation

• In men, this central activation leads to downstream effects that support erectile function
• In women, it increases desire and sensitivity

PT-141 vs. PDE5 Inhibitors

The result is that PT-141 addresses the psychological and neurological components of sexual function, not just the mechanical aspects. This makes it particularly valuable for people whose dysfunction involves low desire or difficulty becoming aroused, rather than purely vascular issues.

PDE5 Inhibitors (Viagra, Cialis) PT-141 (Bremelanotide)

Work peripherally on blood vessels Works centrally in the brain

Increase blood flow to the penis Increases sexual desire and arousal

Require sexual arousal to be effective Can help initiate the arousal response

Do not affect desire Affects both desire and physical response

After subcutaneous injection, PT-141 reaches peak plasma concentration within about one hour and has a half-life of approximately 2.5 hours. Effects can last for several hours to days in some users.

Benefits

Supports Sexual Desire and Arousal

The primary benefit of PT-141 is enhancement of libido at the neurological level. Clinical research demonstrates that PT-141 can increase sexual desire, arousal, and satisfaction by acting on central neural pathways involved in motivation and reward. Its effects are not dependent on visual or tactile stimulation alone.

Addresses Hypoactive Sexual Desire Disorder (HSDD)

PT-141 is FDA-approved for women with acquired, generalized HSDD. Clinical trials show meaningful improvements in sexual desire and reductions in sexual distress compared to placebo.

May Benefit Men with Erectile Dysfunction

Studies indicate that PT-141 can induce erectile responses in men, including those who do not respond adequately to PDE5 inhibitors. Because it acts centrally, PT-141 may complement existing erectile-function therapies rather than replace them.

Rapid Onset and Long-Lasting Effects

PT-141 is typically active within 30–45 minutes after administration, with effects that may persist for up to 24–72 hours depending on dose and individual response.

Neurogenic, Not Vascular

By targeting the brain rather than blood vessels, PT-141 supports both psychological and physiological components of sexual function, making it relevant for individuals whose sexual concerns are driven by stress, mood, or neurochemical imbalance.

Works When PDE5 Inhibitors Fail

Studies show PT-141 can help men who did not respond adequately to Viagra or Cialis. A clinical trial found that combining PT-141 with sildenafil produced a clinically significant enhanced erectile response in men who had failed sildenafil alone.

Addresses Psychological Components

Because PT-141 works on brain pathways rather than blood vessels, it can help with dysfunction rooted in desire, arousal, or psychological factors rather than purely vascular problems.

On-Demand Use

PT-141 is used as needed rather than daily, providing flexibility and control over timing.

Additional Areas of Ongoing Research

Beyond sexual health, melanocortin receptor agonists are being studied for potential roles in appetite regulation, metabolic health, cognitive signaling, and behavioral reinforcement. While early findings are promising, these applications remain investigational and are not currently FDA-approved indications for PT-141.

What the Science Shows

PT-141 has strong clinical trial data, particularly for women with HSDD.

RECONNECT Trials (Phase 3)

Two identical phase 3 randomized controlled trials evaluated PT-141 in premenopausal women with HSDD:

• 1,247 women participated across both studies
• Treatment: 1.75 mg subcutaneous injection as needed for 24 weeks
• Significant improvements in Female Sexual Function Index (FSFI) desire domain scores
• Significant reductions in sexual distress
• These trials led to FDA approval in 2019

Men with Erectile Dysfunction

Multiple studies have evaluated PT-141 in men:

• A study in sildenafil non-responders found PT-141 produced significant improvements in

erectile function

• 33.5% of men treated with PT-141 showed positive clinical results compared to 8.5% on

placebo

• Combination with sildenafil showed enhanced results over either agent alone

Goldstein 2024 Observational Study

A sexual medicine clinic reported outcomes in 21 men using subcutaneous PT-141 off-label:

• Improvements in desire, erection quality, and sexual satisfaction
• Effects noted even in men who had failed other treatments
• Generally well tolerated

Safety Profile from Clinical Trials

The most common side effects observed in trials:

• Nausea: 40% (often decreases with repeated use)
• Flushing: 20%
• Headache: 11%
• Transient blood pressure increase (1–3 mmHg)

Nausea is the primary tolerability issue, typically lasting 1–2 hours after injection and often improving with repeated use.

Dosing Protocol

PT-141 dosing is well established through clinical trials. The FDA-approved dose is 1.75 mg administered subcutaneously. This dose was selected through dose-finding trials that balanced efficacy against side effects (particularly nausea).

Standard Protocol

Setting Dose Timing Frequency Limit

Standard 1.75 mg 45 min before As needed Max 1 per 24 hrs; activity Max 8 per month

Some practitioners and users start with lower doses (1 mg) to assess tolerance, particularly regarding nausea.

Practical Considerations

• Administer at least 45 minutes before anticipated sexual activity
• Effects may last several hours to 24+ hours in some individuals
• Do not redose within 24 hours even if the first dose seems inadequate
• Limit to 8 doses per month to minimize side effects and avoid tolerance

Why the Monthly Limit

The 8-dose monthly maximum reflects clinical trial parameters and concerns about:

• Cumulative side effects
• Potential for hyperpigmentation with frequent use
• Unknown effects of more frequent long-term use
• Blood pressure effects with repeated dosing

Most users find once or twice weekly use adequate for their needs.

Draw Volumes by Vial Size

10 mg Vial (2 mL reconstitution = 5 mg/mL)

Dose Volume Units on Syringe

1.0 mg 0.20 mL 20 units

1.75 mg 0.35 mL 35 units

2.0 mg 0.40 mL 40 units

10 mg Vial (1 mL reconstitution = 10 mg/mL)

Dose Volume Units on Syringe

1.0 mg 0.10 mL 10 units

1.75 mg 0.175 mL 17.5 units

2.0 mg 0.20 mL 20 units

At 1.75 mg per dose with a 10 mg vial, one vial provides approximately 5 to 6 doses.

Reconstitution Instructions

1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. 2. Draw 1 to 2 mL of bacteriostatic water into a sterile syringe. 3. Insert the needle through the rubber stopper at an angle. 4. Direct the stream of water down the inside wall of the vial. 5. Allow the peptide to dissolve without aggressive shaking. 6. Gently swirl if needed until the solution is clear. 7. Label the vial with the date and concentration.

PT-141 dissolves readily in water. The solution should be clear and colorless.

Side Effects and Cautions

Common Side Effects

• Nausea (40%): Most common side effect, typically lasting 1–2 hours. Often decreases

with repeated use. Anti-nausea medication can help.

• Flushing (20%): Temporary redness of skin due to histamine release.
• Headache (11%): Usually mild and temporary.
• Injection site reactions: Redness and irritation at the injection site.

Less Common Effects

• Dizziness
• Fatigue
• Nasal congestion
• Hyperpigmentation (darkening of skin, gums, or breasts with repeated use)

Cardiovascular Effects

PT-141 causes transient increases in blood pressure:

• Average increase: 1–3 mmHg systolic and diastolic
• Peaks 2–4 hours after dosing
• Returns to baseline within hours

This is generally not clinically significant in healthy individuals but is a concern for those with uncontrolled hypertension or cardiovascular disease.

Contraindications and Precautions

Who Should Avoid PT-141

• Individuals with uncontrolled hypertension
• Those with known cardiovascular disease
• People taking medications that significantly affect blood pressure
• Pregnant or breastfeeding women
• Anyone with known hypersensitivity to bremelanotide

Use with Care

• Those with controlled hypertension (monitor blood pressure)
• Individuals prone to nausea
• People with darker skin tones (higher risk of hyperpigmentation)
• Anyone taking naltrexone (PT-141 may reduce naltrexone absorption)

Comparison to Similar Compounds

Compound Mechanism Primary Use Route Onset

PT-141 MC3R/MC4R Desire/arousal SubQ 45 min agonist

Sildenafil PDE5 inhibitor Erectile function Oral 30–60 min

Tadalafil PDE5 inhibitor Erectile function Oral 30 min

Melanotan II MC receptor Tanning/libido SubQ Variable agonist

Kisspeptin GnRH stimulation Hormone release SubQ Variable

PT-141 is unique in targeting the brain’s desire pathways rather than blood flow. It works synergistically with PDE5 inhibitors when both desire and vascular function need support. Melanotan II has similar effects on libido but also causes significant tanning and is not approved for any indication. PT-141 was developed specifically to isolate the sexual effects.

Success Tips

Manage Nausea

Nausea is the main barrier to tolerability. Strategies include:

• Start with a lower dose (1 mg) for first use
• Take anti-nausea medication 30 minutes before PT-141
• Eat a light meal before dosing (not too full, not empty)
• Know that nausea often decreases with repeated use

Set Expectations

PT-141 enhances desire and arousal, but it is not a magic pill. It works best when you create conditions conducive to intimacy. The peptide amplifies what you bring to the situation.

Timing Matters

Allow at least 45 minutes before anticipated activity. Some users find effects take longer to develop fully (1–2 hours). Effects can last many hours, so there is flexibility once the peptide takes effect.

Track Your Response

Note how different doses affect you. Some people respond well to 1 mg while others need the full 1.75 mg. Finding your optimal dose helps balance efficacy and side effects.

Combine Thoughtfully

PT-141 can be used with PDE5 inhibitors for an enhanced effect, but this should be done carefully and preferably under medical supervision. The combination addresses both central (desire) and peripheral (blood flow) aspects of function.

Storage and Handling

Before Reconstitution

• Store lyophilized (powder) vials in the freezer at −20°C
• Can be stored at room temperature for short periods
• Protect from light

After Reconstitution

• Refrigerate at 2°C to 8°C
• Use within 28 days
• Do not freeze after reconstitution
• Discard if solution becomes cloudy or discolored

The FDA-approved product (Vyleesi) comes in prefilled autoinjectors stored at room temperature, but reconstituted peptide solutions should be refrigerated.

Legal Status

United States: FDA-approved in 2019 as Vyleesi for treating HSDD in premenopausal women. Use in men is off-label but common in clinical practice. Available through prescription and as a research compound.

International: Approval status varies by country. Available for research purposes in most regions.

Frequently Asked Questions

Does PT-141 work for men? Yes. While only FDA-approved for women, PT-141 has been studied in men and is used off- label for erectile dysfunction and low libido. Studies show it can help men who have not responded to Viagra or Cialis, and it can enhance results when combined with those medications.

How is PT-141 different from Viagra? Viagra (sildenafil) increases blood flow to the penis by inhibiting the enzyme PDE5. It requires sexual arousal to work. PT-141 works in the brain to increase desire and arousal itself. Viagra addresses the mechanical aspect; PT-141 addresses the motivational aspect. They can be used together.

Will PT-141 give me an erection without stimulation? PT-141 increases desire and can make arousal easier, but it does not typically produce spontaneous erections without any stimulation. Some users report increased spontaneous arousal, but the effect is more about being more easily aroused than about an automatic physical response.

How do I manage the nausea? Nausea is common, especially with early doses. Try starting with 1 mg instead of 1.75 mg. Take anti-nausea medication 30 minutes before dosing. Eat a light meal. Know that nausea typically decreases with repeated use as your body adjusts.

Can I use PT-141 frequently?

The recommended maximum is 8 doses per month (roughly twice weekly). More frequent use raises concerns about cumulative side effects, hyperpigmentation, and unknown long-term effects. Most users find once or twice weekly use adequate.

Will PT-141 cause permanent skin darkening?

Hyperpigmentation is possible with repeated use, particularly in individuals with darker skin tones. This effect is related to melanocortin receptor activation. It is generally reversible if PT- 141 is discontinued, but limiting use to the recommended frequency minimizes risk.

References

8. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899–908. 9. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder. Journal of Sexual Medicine. 2008;5(4):887–897. 10. Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT- 141. International Journal of Impotence Research. 2004;16:51–59. 11. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141. International Journal of Impotence Research. 2004;16:135–142. 12. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health. 2016;12(3):325–337. 13. Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003;994:96–102.